1. Introduction
===============

Licorice is one of the most frequently used natural drugs in Asian traditional medicines. It produces various types of phenolic constituents, in addition to glycyrrhizin and related triterpene glycosides. Recently, the biological activities of licorice extracts and ingredients have attracted many researchers, and their effects in the treatment for different human diseases such as cancer, atherosclerosis, gastric ulcers, hepatitis and immunodeficiency have been summarized in some reviews \[[@B1-molecules-19-03883],[@B2-molecules-19-03883],[@B3-molecules-19-03883]\]. Potential beneficial effects of licorice in common oro-dental diseases were also discussed in a review article \[[@B4-molecules-19-03883]\]. Potent antibacterial activities of licorice phenolics against bacterial strains such as *Helicobacter pylori*, cariogenic bacterial species, *Streptococcus mutans* and *Streptococcus sobrinus*, and periodontopathogenic species, *Porphyromonas gingivalis* and *Prevotella intermedia*, were also reported \[[@B5-molecules-19-03883],[@B6-molecules-19-03883],[@B7-molecules-19-03883],[@B8-molecules-19-03883]\]. Our previous investigation revealed that several naturally occurring compounds showed potent antibacterial effects on methicillin-resistant *Staphylococcus aureus* (MRSA) \[[@B9-molecules-19-03883],[@B10-molecules-19-03883],[@B11-molecules-19-03883]\], and some of the licorice phenolics, such as licoricidin (**1**), showed suppressing effects on the oxacillin resistance of MRSA \[[@B11-molecules-19-03883]\].

Among drug-resistant bacteria vancomycin-resistant *Enterococci* (VRE) is a serious menace for patients in hospitals. Just a few drugs such as linezolid show bacteriostatic activity against vancomycin-resistant strains of E. faecium and E. faecalis, and a combination of quinupristin and dalfopristin, which have bactericidal activity against most drug-resistant *staphylococci*, *streptococci*, and *pneumococci*, appears to be bacteriostatic against E. faecium, and is not active against Enterococcus faecalis \[[@B12-molecules-19-03883]\]. Therefore, we have investigated on the effective constituents of licorice (licorice based on *Glycyrrhiza uralensis*) on VRE, and found that some phenolics among them had potent to moderate antibacterial effects on VRE. Since two compounds among the phenolics isolated from licorice have not yet been characterized, their structures were established in the present study. This paper describes structural evidence of the two compounds and effects of licorice phenolics on VRE. Worthy that antimicrobial activities of extracts of leaves and roots of *Glycyrrhiza* species were previously studied \[[@B13-molecules-19-03883],[@B14-molecules-19-03883]\] against several bacterial strains including *Enterococcus faecalis*. Although a paper reported gancaonin I (**17**) as a compound with the anti-VRE effect \[[@B15-molecules-19-03883]\], our study revealed several pure phenolic compounds from licorice should also be considered as lead compound candidates for new anti-VRE drugs, as shown below.

2. Results and Discussion
=========================

The licorice phenolics ([Figure 1](#molecules-19-03883-f001){ref-type="fig"} and [Figure 2](#molecules-19-03883-f002){ref-type="fig"}) were isolated from the ethyl acetate extract in the following way: the extract was subjected to countercurrent distribution with CHCl~3~--CH~3~OH--H~2~O, and the less polar fractions were respectively chromatographed on silica gel, ODS-gel, and MCI-gel CHP-20P, to give licoricidin (**1**) \[[@B16-molecules-19-03883]\], allolicoisoflavone B (**2**) \[[@B17-molecules-19-03883]\], 3\'-(*γ*,*γ*-dimethylallyl)-kievitone (**3**) \[[@B18-molecules-19-03883]\], 7-*O*-methylluteone (**4**) \[[@B19-molecules-19-03883]\], kaempferol 3-*O*-methyl ether (**5**) \[[@B20-molecules-19-03883]\], and kaempferol (**6**) \[[@B21-molecules-19-03883]\], and fractions containing phenolics. Those fractions were purified by preparative TLC on silica gel or by preparative HPLC to give isolicoflavonol (**7**) \[[@B22-molecules-19-03883]\], isoglycycoumarin (**8**) \[[@B23-molecules-19-03883]\], licoarylcoumarin (**9**) \[[@B24-molecules-19-03883]\], formononetin (**10**) \[[@B25-molecules-19-03883]\], and 6\"-*O*-acetylliquiritin (**11**) \[[@B26-molecules-19-03883]\]. On the other hand, the remaining part of the ethyl acetate fraction was directly subjected to column chromatography on ODS-gel, and fractions from the column were further purified by column chromatography on MCI-gel CHP-20P, and by preparative HPLC or preparative TLC, to give liquiritin (**12**) \[[@B27-molecules-19-03883]\], *p*-hydroxybenzoic acid (**13**), semilicoisoflavone B (**14**) \[[@B28-molecules-19-03883]\], glycyrol (**15**) \[[@B29-molecules-19-03883]\], glycyrin (**16**) \[[@B29-molecules-19-03883]\], gancaonin I (**17**) \[[@B30-molecules-19-03883]\], isoglycyrol (**18**) \[[@B31-molecules-19-03883]\], liquiritigenin (**19**) \[[@B27-molecules-19-03883]\], gancaonin G (**20**) \[[@B32-molecules-19-03883]\], 3-(*p*-hydroxyphenyl)-7-methoxycoumarin (**21**) \[[@B33-molecules-19-03883]\], 6,8-diprenylorobol (**22**) \[[@B34-molecules-19-03883]\], isoliquiritin (**23**) \[[@B35-molecules-19-03883]\], 8-(*γ*,*γ*-dimethylallyl)-wighteone (**24**) \[[@B36-molecules-19-03883]\], glicoricone (**25**) \[[@B37-molecules-19-03883]\], glycycoumarin (**26**) \[[@B38-molecules-19-03883]\], licocoumarone (**27**) \[[@B29-molecules-19-03883]\], licoricone (**28**) \[[@B39-molecules-19-03883]\], glyasperin D (**29**) \[[@B40-molecules-19-03883]\], isoangustone A (**30**) \[[@B41-molecules-19-03883]\], and two additional compounds temporarily named compounds A (**31**), and B (**32**). Since several phenolics from licorice display potent antibacterial effects against methicillin-resistant *Staphylococcus aureus* (MRSA), and also show suppressing effects on the oxacillin resistance of MRSA, as we have reported previously \[[@B11-molecules-19-03883]\], we have also investigated the effect of these licorice phenolics on VRE.

![Chemical structures of compounds **1**‒**13** and **32** isolated from root and stolon of *Glycyrrhiza uralensis*.](molecules-19-03883-g001){#molecules-19-03883-f001}

![Chemical structures of compounds **14**‒**31** isolated from root and stolon of *Glycyrrhiza uralensis*.](molecules-19-03883-g002){#molecules-19-03883-f002}

2.1. Structures of New Compounds
--------------------------------

Compound A (**31**, [Figure 3](#molecules-19-03883-f003){ref-type="fig"}) was obtained as a pale-yellow microcrystalline powder. The high-resolution fast-atom bombardment mass spectroscopy (HR-FAB-MS) data (found *m*/*z* 353.0990 \[M+H\]^+^, calcd. 353.1025), indicated that this compound has a molecular formula C~20~H~16~O~6~. The UV spectrum showed absorption maxima at 259 (log ε, 4.45) and 345 nm (log ε, 4.23), which is similar to glycyrol, suggested that it has a 3-arylcoumarin or related coumestan skeleton as the chromophore. The ^1^H-NMR spectrum ([Table 1](#molecules-19-03883-t001){ref-type="table"}) showed a one-proton singlet at *δ*~H~ 6.25 (H-4) and three protons forming an ABX system at *δ*~H~ 6.80 (1H, d, *J* = 2.4 Hz, H-10), *δ*~H~ 6.71 (1H, dd, *J* = 2.4, 8.4 Hz, H-8), and *δ*~H~ 7.25 (1H, d, *J* = 8.4 Hz, H-1) in the aromatic region, indicating the presence of penta-substituted and tri-substituted phenyl rings in the molecule. The absence of the H-11a signal (corresponding to H-4 of the 3-arylcoumarin skeleton) indicated the coumestan \[[@B29-molecules-19-03883],[@B31-molecules-19-03883]\] structure for this compound. The remaining signals at *δ*~H~ 1.60, 1.77 (3H each, s, dimethyl at C-3\'), *δ*~H~ 3.12 (2H, d, *J* = 6.6 Hz, methylene at C-1\'), and *δ*~H~ 5.07 (1H, t, *J* = 6.6 Hz, methine at C-2\') in the aliphatic proton region are corresponding to the presence of a *γ*,*γ*-dimethylallyl (prenyl) group in the molecule. The signal pattern in the ^1^H-NMR spectrum of **31** is similar to that of glycyrol (**15**) except that a methoxyl signal observed in the spectrum of **15** is absent in that of compound A. Therefore, the structure of demethylglycyrol (**31**) was assigned for this compound.

![HMBC correlations observed for compound A (demethylglycyrol, **31**).](molecules-19-03883-g003){#molecules-19-03883-f003}

molecules-19-03883-t001_Table 1

###### 

600 MHz NMR Spectroscopic Data for Demethylglycyrol (**31**) (acetone-d*~6~*, 27 °C), and 5,7-Di-*O*-methylluteone (**32**) (CD~3~OD, 27 °C).

             Demethylglycyrol (31)   5,7-Di-*O*-methylluteone (32)                                                           
  ---------- ----------------------- ------------------------------- ------------------- ------------- --------------------- -----------------------
  C-1        160.4, C                                                                                                        
  C-2        113.9, C                                                                    170.1, CH     7.95, s               3, 4, 1\'
  C-3        158.5, C                                                                    119.9, C                            
  C-4        99.4, CH                6.25, s                         2, 3, 4a, 11b       178.8, C                            
  C-4a       156.4, C                                                                    106.5, C                            
  C-5                                                                                    159.2, C                            
  C-6        160.1, C                                                                    115.6, C                            
  C-6a       104.0, C                                                                                                        
  C-6b       114.9, C                                                                                                        
  C-7        98.4, CH                6.80, d (2.4)                                       160.4, C                            
  C-8        111.9, CH               6.71, dd (2.4, 8.4)                                 96.4, CH      6.34, s               6, 7, 4a, 8a
  C-8a                                                                                   156.7, C                            
  C-9        156.6, C                                                                                                        
  C-10       120.0, CH               7.25, d (8.4)                                                                           
  C-10a      156.1, C                                                                                                        
  C-11a      158.6, C                                                                                                        
  C-11b      104.1, C                                                                                                        
  C-1\'      23.2, CH~2~             3.12, d (6.6)                   1, 2, 3, 2\', 3\'   117.5, C                            
  C-2\'      125.1, CH               5.07, t (6.6)                                       160.0, C                            
  C-3\'      130.5, C                                                                    128.2, CH     8.02, d (8.4)         2\', 4\'
  C-4\'      25.8, CH~3~             1.60, s                         2\',3\', 5\'        157.1, C                            
  C-5\'      17.9, CH~3~             1.77, s                         2\', 3\', 4\'       116.8, CH     6.92, dd (2.4, 8.4)   1\'
  C-6\'                                                                                  103.3, CH     6.82, d (2.4)         2\'
  C-1\'\'                                                                                23.5, CH~2~   3.38, d (6.6)         5, 6, 7, 2\'\', 3\'\'
  C-2\'\'                                                                                125.2, CH     5.14, t (6.6)         
  C-3\'\'                                                                                130.9, C                            
  C-4\'\'                                                                                17.7, CH~3~   1.73, s               2\'\', 3\'\'
  C-5\'\'                                                                                25.7, CH~3~   1.64, s               2\'\', 3\'\'
  5-OCH~3~                                                                               61.3, CH~3~   3.78, s               5
  7-OCH~3~                                                                               55.9, CH~3~   3.43, s               7

*^a^* HMBC correlations, optimized for 5 Hz, are from proton(s) stated to the optimized carbon.

The ^13^C-NMR spectrum showed five carbon signals ascribable to a prenyl group \[*δ*~C~ 17.9, 25.8 (dimethyl at C-3\'), *δ*~C~ 23.3 (C-1\'), *δ*~C~ 125.1 (C-2\'), *δ*~C~ 130.5 (C-3\')\], in addition to fifteen carbon signals assignable to the coumestan skeleton (see [Table 1](#molecules-19-03883-t001){ref-type="table"}). Four carbon signals at *δ*~C~ 104.1 (C-11b), *δ*~C~ 113.9 (C-2), *δ*~C~ 156.4 (C-4a), and *δ*~C~ 158.5 (C-3) among the *sp*^2^ carbon signals are correlated with the aromatic proton at *δ*~H~ 6.25 (H-4) in the ^1^H-detected multiple bond correlation (HMBC) spectrum ([Figure 3](#molecules-19-03883-f003){ref-type="fig"}). On the other hand, correlations of the methylene proton signal at *δ*~H~ 3.12 (H-1\') with the carbon signals at *δ*~C~ 113.9 (C-2), *δ*~C~ 158.5 (C-3), and *δ*~C~ 160.4 (C-1), along with the correlations with the allylic carbon signals at *δ*~C~ 125.1 (C-2\') and *δ*~C~ 130.5 (C-3\'), were also observed in the HMBC spectrum. These correlations are coincided with the location of the prenyl group at C-2.

The substitution pattern of the hydroxyl and prenyl groups on the coumestan skeleton was further confirmed by chemical evidence. Compound A (**31**) was methylated (see Experimental Section) to afford the methyl derivative **31a** ([Figure 2](#molecules-19-03883-f002){ref-type="fig"}), which was identical with the compound obtained by methylation of the known compound glycyrol (**15**). The structure of demethylglycyrol (**31)** for compound A was thus established.

Compound B (**32**, ([Figure 4](#molecules-19-03883-f004){ref-type="fig"}) was also obtained as a pale-yellow microcrystalline powder. Its HR-FAB-MS data (Found 383.1448 \[M+H\]^+^, Calcd 383.1495) indicated that this compound has a molecular formula C~22~H~22~O~6~. The UV spectrum of **32** with the absorption maxima at 258 (log ε, 4.08) 291sh, and 340 nm (log ε, 3.93) suggested that it has an isoflavone skeleton as the chromophore. The ^1^H-NMR spectrum showed two one-proton singlets a *δ*~H~ 7.97 (H-2) and *δ*~H~ 6.38 (H-8), and three protons forming an ABX system at *δ*~H~ 6.91 (1H, d, *J* = 2.4 H~Z~, H-3\'), *δ*~H~ 6.99 (1H, dd, *J* = 2.4, 8.4 Hz, H-5\'), and *δ*~H~ 8.02 (1H, d, *J* = 8.4 Hz, H-6\') in the aromatic-proton region, corresponding to the isoflavone skeleton. The presence of the prenyl group was also indicated by a set of aliphatic protons at *δ*~H~ 1.60, 1.69 (3H each, s, dimethyl at C-3\'\'), *δ*~H~ 3.21 (2H, d, *J* = 6.6 Hz, H-1\'\'), and *δ*~H~ 5.14 (1H, t, *J* = 6.6 Hz, H-2\'\'). The presence of the two methoxyl groups was shown by the signals at *δ*~H~ 3.40 and *δ*~H~ 3.76 (3H each, s). This ^1^H signal pattern for compound B was closely similar to that of licoricone (**28**), suggesting a structure isomeric to **32**. The ^13^C-NMR spectrum (in CD~3~OD) of compound (**32**), however, was discriminable from that of **28**. Compound B (**32**) showed the ^13^C signals of the isoflavone skeleton \[*δ*~C~ 96.4 (C-8), *δ*~C~ 103.3 (C-3\'), *δ*~C~ 106.5 (C-4a), *δ*~C~ 115.6 (C-6), *δ*~C~ 116.8 (C-5\'), *δ*~C~ 117.5 (C-1\'), *δ*~C~ 119.9 (C-3),*δ*~C~ 128.2 (C-6\'),*δ*~C~ 156.7 (C-8a), *δ*~C~ 157.1 (C-4\'), *δ*~C~ 159.2 (C-5), *δ*~C~ 160.0 (C-2\'), *δ*~C~ 160.4 (C-7), *δ*~C~ 170.1 (C-2),*δ*~C~ 178.8 (C-4) (see [Table 1](#molecules-19-03883-t001){ref-type="table"})\], in addition to the prenyl \[*δ*~C~ 17.7, 25.4 (dimethyl at *δ*~C~ C-3\")*δ*~C~ 23.5 (C-1\"),*δ*~C~ 125.2 (C-2\"), *δ*~C~ 130.9 (C-3\")\] and methoxyl groups (*δ*~C~ 55.9 and *δ*~C~ 61.3). Among the isoflavone skeleton signals of compound B (**32**), the chemical shift of C-2 (*δ*~C~ 170.1) showed a large difference from the corresponding carbon signal (*δ*~C~ 157.9) of licoricone (**28**) \[[@B39-molecules-19-03883]\]. The assignment of C-2 in **32** was supported by the HMBC correlations of H-2 signal (*δ*~H~ 7.95) with carbon signals of C-3 (*δ*~C~ 119.9), C-4 (*δ*~C~ 178.8), and C-1\' (*δ*~C~ 117.5), and correlations of H-5\' signal (*δ*~H~ 6.92) with carbon signals of C-1\' (*δ*~C~ 117.5). The HMBC spectrum also showed correlations of H-8 signal (*δ*~H~ 6.34) with carbon signals of C-4a (*δ*~C~ 106.5),C-6 (*δ*~C~ 115.6), C-8a (*δ*~C~ 156.7), and C-7 (*δ*~C~ 160.4), and that of H-1" (*δ*~H~ 3.38) with those of C-6 (*δ*~C~ 115.6), C-2" (*δ*~C~ 125.2),C-5 (*δ*~C~ 159.2), and C-7 (*δ*~C~ 160.4), substantiating the location C-6 for the prenyl group. The HMBC correlations ([Figure 4](#molecules-19-03883-f004){ref-type="fig"}) for the methoxyl groups \[*δ*~H~ 3.78 with C-5 (*δ*~C~ 61.3), and *δ*~H~ 3.43 with C-7 (*δ*~C~ 55.9)\] emphasized their locations at C-5 and C-7. The structure of 5,7-di-*O*-methylluteone (**33**) was thus assigned for compound B.

![HMBC correlations observed for compound B (5,7-di-*O*-methylluteone, **32**).](molecules-19-03883-g004){#molecules-19-03883-f004}

2.2. Antibacterial Effects of Licorice Phenolics on VRE
-------------------------------------------------------

*E. faecium* FN-1 and *E. faecalis* NCTC 12201 strains were used in this study. The antibacterial effects of the licorice phenolics on the VRE strains were estimated using the liquid dilution method. Although except for linezolid almost all of the tested antibacterial standard drugs showed high minimum inhibitory concentration (MIC) values against at least one of the two used strains as shown in [Table 2](#molecules-19-03883-t002){ref-type="table"}, among the licorice phenolics examined in this study, a 2-arylcoumarin, gancaonin I (**17**) showed potent antibacterial effects against *E. faecium* (MIC of 8 μg/mL), and *E. faecalis* (MIC of 16 μg/mL). Additionally, two 3-arylcoumarins, licoarylcoumarin (**9**) and glycycoumarin (**26**) showed low MIC values (16 μg/mL) for *E. faecium* and *E. faecalis*. An isoflavone semilicoisoflavone B (**14**), and an isoflavan glyasperin D (**29**) showed potent (16 μg/mL) to moderate MIC (32 μg/mL) for *E. faecium*. Flavonols, flavanones, and chalcones showed no or weak (\~128 μg/mL) antibacterial effects. Noticeable that the compounds with two or three phenolic hydroxyl groups accompanied by a prenyl group showed potent anti-VRE effects relative to those of the other structural features. Since coumestans such as isoglycyrol (**18**) and demethlglycyrol (**31**) showed weak antibacterial effects relative to those of 3-arylcoumarins, the structural rigidity may cause decrease of the effects.

molecules-19-03883-t002_Table 2

###### 

Antibacterial effects of licorice phenolics on enterococci shown by their minimum inhibitory concentrations (μg/mL).

  Compounds                            Bacterial Strains   
  ------------------------------------ ------------------- --------
  Flavonols and related compounds                          
  Kaempferol-3- *O*-methyl ether (c)   \>128               \>128
  Kaempferol ( **6**)                  \>128               \>128
  Isolicoflavonol ( **7**)             \>128               128
  Flavanones                                               
  6\"-O-Acetylliquiritin ( **11**)     \>128               \>128
  Liquiritin ( **12**)                 \>128               128
  Liquiritigenin ( **19**)             \>128               \>128
  Chalcone                                                 
  Isoliquiritin ( **23**)              \>128               \>128
  Isoflavones and Isoflavans                               
  Allolicoisoflavone B ( **2**)        \>128               128
  Formononetin ( **10**)               \>128               \>128
  Semilicoisoflavone B ( **14**)       32                  64
  5,7-Di- *O*-Methylluteone (**32**)   64                  128
  Gancaonin G ( **20**)                64                  128
  6,8-Diprenylorobol ( **22**)         128                 128
  Glicoricone ( **25**)                \>128               \>128
  Licoricone ( **28**)                 128                 \>128
  Glyasperin D ( **29**)               32                  64
  3-Arylcoumarins                                          
  Isoglycycoumarin ( **8**)            64                  \>128
  Licoarylcoumarin ( **9**)            16                  16
  Glycyrin ( **16**)                   16                  32
  Glycycoumarin ( **26**)              16                  16
  Coumestans                                               
  Glycyrol ( **15**)                   \>128               \>128
  Isoglycyrol ( **18**)                32                  64
  Demethlglycyrol ( **31**)            64                  64
  2-Arylcoumarones                                         
  Gancaonin I ( **17**)                8                   16
  Licocoumarone ( **27**)              32                  32
  Others                                                   
  *p*-Hydroxybenzoic acid (**13**)     \>128               128
  Standard antibacterial drugs                             
  Erythromycin                         \>1024              \>1024
  Norfloxacin                          \>128               4
  Vancomycin                           \>100               \>100
  Linezolid                            2.5                 2.5
  Imipenem                             \>64                2
  Tetracycline                         64                  128
  Oxacillin                            \>1024              256
  Gentamicin                           \>1024              \>1024

3. Experimental
===============

3.1. General
------------

UV spectra were recorded on a JASCO V-530 spectrometer. ESI-MS measurements were performed on an API-4000 instrument. HR-FAB-MS measurements were conducted on a JEOL JMS-700 MStation with a mixture of *m*-nitrobenzyl alcohol and dithiothreitol as the matrix. ^1^H- and ^13^C-NMR spectra were recorded on an Agilent INOVA 600AS instrument (600 MHz for ^1^H, and 151 MHz for ^13^C), and the chemical shifts were given in *δ* (ppm) downfield from tetramethylsilane, based on those of the solvent signals \[*δ*~H~ 2.04 and *δ*~C~ 29.8 for (CD~3~)~2~CO, and *δ*~H\ 3.30\ and\ *δ*~C~\ 49.8\ for\ CD~3~OD).\ Optical\ rotations\ were\ measured\ on\ a\ JASCO\ DIP-1000\ digital\ polarimeter.\ Normal-phase\ analytical\ HPLC\ was\ performed\ on\ an\ YMC\ SIL-003\ (4.6\ mm\ i.d.\ ×\ 250\ mm)\ column\ (YMC,\ Kyoto,\ Japan)\ with\ *n*-hexane--CH~3~OH--tetrahydrofuran--formic\ acid\ (55:33:11:1,\ *v*/*v*)\ containing\ oxalic\ acid\ (450\ mg/L)\ as\ the\ eluent\ at\ the\ ambient\ temperature.\ Flow\ rate\ was\ set\ at\ 1.5\ mL/min.\ Reversed-phase\ analytical\ HPLC\ was\ conducted\ on\ an\ YMC\ ODS-A\ 302\ (4.6\ mm\ i.d.\ ×\ 250\ mm)\ column\ with\ 10\ mM\ H~3~PO~4~--10\ mM\ KH~2~PO~4~--CH~3~CN--CH~3~COOH\ (35:35:28:2,\ *v*/*v*)\ as\ the\ eluent\ at\ 40\ °C\ Flow\ rate\ was\ set\ at\ 1.0\ mL/min.\ Preparative\ HPLC\ was\ performed\ on\ an\ YMC\ ODS-A324\ (10\ mm\ i.d.\ ×\ 300\ mm)\ column\ with\ H~2~O--CH~3~CN--CH~3~COOH\ (45:50:5,\ *v*/*v*)\ as\ the\ eluent.\ Detection\ for\ HPLC\ was\ effected\ with\ UV\ absorption\ at\ 280\ nm.\ Silica\ gel\ (YMC),\ Toyopearl\ HW-40\ (Coarse\ grade)\ (TOSOH,\ Tokyo,\ Japan),\ YMC-gel\ ODS-A\ (S,\ 75\ μm)\ (YMC),\ and\ MCI-gel\ CHP-20P\ (Mitsubishi\ Chemical,\ Tokyo,\ Japan)\ were\ used\ for\ column\ chromatography.\ Sep-Pak\ C18\ short\ cartridges\ (Waters,\ Milford,\ PA,\ USA)\ were\ also\ used\ for\ purification\ of\ compounds.~

3.2. Plant Material
-------------------

The crude drug used in this study is Tohoku Licorice (root and stolon of *Glycyrrhiza uralensis*), purchased from Tochimoto-tenkai-do (Osaka, Japan) (Lot No. 002009037), and the specimen GU-07112011(NEL) was kept at the Medicinal Plant Garden, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.

3.3. Extraction and Isolation
-----------------------------

Tohoku Licorice (1.0 kg) was pulverized and defatted with *n*-hexane (3 L × 2), and then with ethyl acetate (3 L × 2). A part (5 g) of the ethyl acetate extract (46.4 g) was subjected to the countercurrent distribution (*n* = 4, *r* = 4) with the solvent system CHCl~3~--CH~3~OH--H~2~O (7:13:8, *v*/*v*), to give 8 fractions \[Lower phase (L1--L4) and upper phase (U1--U4) fractions with the following order of the polarity, L1 (3.93 g) \< L2 (0.53 g) \< L3 (101 mg) \< L4 (69 mg) \< U4 (50 mg) \< U3 (59 mg) \< U2 (71 mg) \< U1 (51 mg)\]. The L1 fraction was subjected to column chromatography on silica gel (3.0 cm i.d. × 30 cm) with increasing concentrations of CH~3~OH in CHCl~3~, to give 58 fractions. Combined fractions 10--13 (0.47 g) were subjected to column chromatography on ODS-gel (1.1 i.d. × 42 cm) with increasing concentrations of CH~3~OH in H~2~O, and the eluate with 20% CH~3~OH in H~2~O (155 mg) was further separated by column chromatography on MCI-gel CHP-20P (1.1 i.d. × 40 cm) with increasing concentrations of CH~3~OH in H~2~O, to give licoricidin (**1**) (10.2 mg), allolicoisoflavone B (**2**) (4.5 mg), and 3\'-(*γ*,*γ*-dimethylallyl)-kievitone (**3**) (3.4 mg). The eluate with 25% CH~3~OH in H~2~O (43 mg) from the ODS-gel column was purified by preparative TLC on silica gel with CHCl~3~--CH~3~OH (9:1) to give isolicoflavonol (**7**) (3.1 mg), isoglycycoumarin (**8**) (2.5 mg), and licoarylcoumarin (**9**) (5.8 mg). The L2 fraction from the countercurrent distribution was subjected to column chromatography on silica gel (3.0 i.d. × 30 cm) with increasing concentrations of CH~3~OH in CHCl~3~, to give 25 fractions. Combined fractions 7--10 (0.18 g) were chromatographed on an ODS-gel column (1.1 i.d. × 42 cm) with increasing concentrations of CH~3~OH in H~2~O, and the eluate with 20% CH~3~OH in H~2~O (66 mg) was further chromatographed on an MCI-gel CHP-20P column (1.1 i.d. × 40 cm) with increasing concentrations of CH~3~OH in H~2~O, to give 7-*O*-methylluteone (**4**) (1.9 mg), kaempferol 3-*O*-methyl ether (**5**) (3.1 mg), and kaempferol (**6**) (6.8 mg). The eluate with 25% CH~3~OH in H~2~O (20 mg) from the ODS-gel column was purified by preparative TLC on silica gel with CHCl~3~--CH~3~OH (9:1), to give formononetin (**10**) (1.3 mg). The eluate with 30% CH~3~OH in H~2~O (10 mg) from the ODS-gel column was purified by preparative HPLC to give 6\"-*O*-acetylliquiritin (**11**) (3.8 mg).

Separately, the ethyl acetate extract (40 g) from Tohoku Licorice was subjected to column chromatography on ODS-gel (2.2 i.d. × 75 cm) with increasing concentrations of CH~3~OH in H~2~O and then with increasing concentrations of CHCl~3~ in CH~3~OH. The eluate with 10% CHCl~3~ in CH~3~OH (4.1 g) was subjected to column chromatography on MCI-gel CHP-20P (2.2 i.d. × 45 cm) with increasing concentrations of CH~3~OH in H~2~O, and the eluate with 15% CH~3~OH in H~2~O (86 mg) was purified by preparative HPLC, to give liquiritin (**12**) (8.3 mg). The eluate with 30% CH~3~OH in H~2~O (53 mg) was purified by preparative TLC on silica gel with CHCl~3~--CH~3~OH, to give *p*-hydroxybenzoic acid (**13**) (6.9 mg) and semilicoisoflavone B (**14**) (2.0 mg). The eluate with 50% CHCl~3~ in CH~3~OH (3.6 g) was subjected to column chromatography on MCI-gel CHP-20P (2.2 i.d. × 45 cm) with increasing concentrations of CH~3~OH in H~2~O, and fractions 85 (48 mg), 94 (42 mg), 96 (40 mg), 137 (22 mg), 236--237 (19 mg), and 343--347 (59 mg) were respectively purified by preparative HPLC to give glycyrol (**15**) (4.1 mg), glycyrin (**16**) (15.4 mg) (from fraction 85), compound B (5,7-di-*O*-Methylluteone **32**) (3.5 mg), gancaonin I (**17**) (5.9 mg), isoglycyrol (**18**) (4.2 mg) (from fraction 94), liquiritigenin (**19**) (8.5 mg), gancaonin G (**20**) (3.1 mg), 3-(*p*-hydroxyphenyl)-7-methoxycoumarin (**21**) (1.2 mg), 6,8-diprenylorobol (**22**) (4.2 mg) (from fraction 96), isoliquiritin (**23**) (2.3 mg), 8-(*γ*,*γ*-dimethylallyl)-wighteone (**24**) (1.9 mg) (from fraction 137), compound A (Demethylglycyrol, **31**) (1.8 mg), glicoricone (**25**) (3.9 mg) (from combined fractions 236--237), glycycoumarin (**26**) (5.3 mg), licocoumarone (**27**) (7.9 mg), licoricone (**28**) (2.1 mg), glyasperin D (**29**) (3.5 mg) and isoangustone A (**30**) (4.5 mg) (from combined fractions 343--347).

3.4. Spectral Data
------------------

Compound A (demethylglycyrol, **31**): A pale-yellow, microcrystalline powder (MeOH); mp 265 °C; UV (MeOH) λ~max~ (log ε) 210 (4.47), 259 (4.45), 345 (4.23) nm; ^1^H- and ^13^C-NMR data see [Table 1](#molecules-19-03883-t001){ref-type="table"}; ESI-MS *m*/*z* 353 (\[M+H\]^+^); HR-FAB-MS *m*/*z* 353.0990 (\[M+H\]^+^) (Calcd. for C~20~H~17~O~6~, 353.1025).

Compound B (5,7-di-*O*-methylluteone, **32**): A pale-yellow, microcrystalline solid (MeOH); mp 205 °C; UV (MeOH) λ~max~ (log ε) 210 (4.15), 258 (4.08), 291 (sh), 340 (3.93) nm; ^1^H- and ^13^C-NMR data see [Table 1](#molecules-19-03883-t001){ref-type="table"}; ESI-MS *m*/*z* 383 (\[M+H\]^+^), HR-FAB-MS *m*/*z* 383.1448 (\[M+H\]^+^) (Calcd. for C~22~H~23~O~6~, 383.1495).

3.5. Methylation of Compound A and Glycyrol
-------------------------------------------

Methylation of compound A (**31**) was carried out as shown in the literature \[[@B42-molecules-19-03883]\]. Briefly, a solution of compound A (1.5 mg) in EtOH was treated by TMS-diazomethane at room temperature 3 h. The reaction mixture was concentrated under reduced pressure to a residue which was purified by TLC on silica gel (CHCl~3~--MeOH, 15:1, *v*/*v*), to give three compounds: glycyrol (0.5 mg), the monomethyl derivative of compound A (0.3 mg) (identified by ^1^H-NMR), and the corresponding trimethyl derivative (0.3 mg) (**31\'**, [Figure 2](#molecules-19-03883-f002){ref-type="fig"}). Compound A-3Me (**31\'**): ^1^H-NMR (acetone-*d*~6~): *δ*~H~ 1.66 and *δ*~H~ 1.81 (each 3H, s, -CH3 × 3), *δ*~H~ 3.44 (2H, d, *J* = 7 Hz, H-1\"), *δ*~H~ 4.00, 4.01, 4.02 (each 3H, s, ‒OCH~3~ × 3), *δ*~H~ 5.22 (1H, t, *J* = 7 Hz, H-2\'\'), *δ*~H~ 6.95 (1H, s, H-8), *δ*~H~ 7.05 (1H, dd, *J* = 2, 8 H~Z~, H-5\'), *δ*~H~ 7.23 (1H, d,*J* = 2 Hz, H-3\'), *δ*~H~ 7.82 (1H, d, *J* = 8 Hz, H-6\'), *δ*~H~ 7.97 (1H, s, H-2). This compound is identical with that obtained by analogous treatment of glycyrol (**15**).

3.6. Antibacterial Assay
------------------------

Estimation of antibacterial effects of licorice phenolics on vancomycin-resistant *Enterococcus* strains was carried out as has been described in the literature \[[@B9-molecules-19-03883],[@B43-molecules-19-03883],[@B44-molecules-19-03883]\]. *Enterococcus faecium* FN-1 and *E. faecalis* NCTC 12201 used in this study were vancomycin resistant ones which were kindly provided by Dr. Y. Ike, Gunma University. The bacterial cells, pre-cultured in Mueller-Hinton broth at 37 °C under aerobic condition, were incubated in the presence of compounds with the concentrations obtained by serial two-fold dilution at 37 °C without shaking in 96-well plates in the same broth for 24 h. The inocula were adjusted to yield a final cell density of about 10^5^ CFU. The standard antibacterial drugs erythromycin, norfloxacin, vancomycin, linezolid, imipenem, tetracycline, oxacillin and gentamycin were used as reference compounds for the tested strains *Enterococcus faecium* FN-1 and *E. faecalis* NCTC 12201 in the present study. The minimum inhibitory concentrations (MICs) were estimated as the lowest concentrations where the bacterial cells were not observed visually. The MIC values were determined based on triplicate experiments.

4. Conclusions
==============

Previous reports have shown that phenolics from licorice are potent antibacterial against MRSA \[[@B11-molecules-19-03883],[@B45-molecules-19-03883]\], and some of them showed suppressing effects on the oxacillin resistance of MRSA \[[@B11-molecules-19-03883]\]. To discover bioactive natural compounds from natural source, *Glycyrrhiza uralensis* was investigated, affording a new coumestan **31** and an isoflavone **32**, together with three known flavanols **5**‒**7**, three flavanones **11**, **12** and **19**, a chalcone **23**, eight isoflavones **2**, **10**, **14**, **20**, **22**, **25**, **28** and **32**, one isoflavan **29**, four 3-arylcoumarins **8**, **9**, **16** and **26**, three coumestans **15**, **18** and **31**, two 2-arylcoumarins **17** and **27** and *p*-hydroxybenzoic acid (**13**). Vancomycin-resistant *Enterococci* (VRE) is a serious drug-resistant bacteria, and just a few compounds such as linezolid, or a combination of quinupristin and dalfopristin have been used for treatments of diseases caused by them \[[@B12-molecules-19-03883]\]. Therefore we have also investigated the effectiveness of the thirty two licorice phenolics isolated in this study on VRE, and we found that several compounds possesses moderate to potent antibacterial activity against VRE, and the 2-arylcoumarone gancaonin I (**17**) have the highest potency against the tested strains *E. faecium* (MIC of 8 μg/mL), and *E. faecalis* (MIC of 16 μg/mL), which is in agreement with the previously reported potent activity for a 2-arylcoumarin, gancaonin I (**17**) \[[@B15-molecules-19-03883]\]. In addition to that, two 3-arylcoumarins, licoarylcoumarin (**9**) and glycycoumarin (**26**), also showed comparable antibacterial effects on *E*. *faecalis* (16 μg /mL). These findings could be useful in developing antibacterial agents from licorice and its various active phenolics. Besides the well-known traditional uses of licorice and the various reported biological effects \[[@B1-molecules-19-03883],[@B2-molecules-19-03883],[@B3-molecules-19-03883],[@B4-molecules-19-03883],[@B5-molecules-19-03883],[@B6-molecules-19-03883],[@B7-molecules-19-03883],[@B8-molecules-19-03883]\], a recent study has added that several licorice phenolics exhibit higher tumor-specific cytotoxic effects \[[@B46-molecules-19-03883]\]. However, further specific investigations on the safety of the pure licorice phenolics for human are awaited.
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